Sanofi is a large pharmaceutical company with strong 16% operating margins, 221% free cash flow conversion, and 3 of 4 recent earnings beats, but faces a confirmed death cross with falling on-balance volume and a dividend payout ratio of 552% that appears structurally unsustainable.
Thesis pillars
- Strong Margins Exceptional Cash Conversion↓Deteriorating
- Three Consecutive Earnings Beats↑Improving
- Death Cross Confirmed Downtrend↑Improving
- +1 more pillar — see the Why tab for full reasoning
Sanofi (SNY) Stock Analysis
Range Bound setup
Healthcare · Drug Manufacturers - General
Hold if already holding. Not a fresh buy at $43.00, but acceptable to hold if already in. Reasons: Thin upside margin: 8.2%; Weak growth.
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib)... Read more
Hold if already holding. Not a fresh buy at $43.00, but acceptable to hold if already in. Reasons: Thin upside margin: 8.2%; Weak growth. Chart setup: RSI 46 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Score 5.7/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 83d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: moderate.
Recent developments
updated 2026-08-08Recent Developments — Sanofi
Latest news
- NEWS Sanofi SA (SNY) Q4 2023 Earnings Report - Results, Call & Slides - TipRanks — TipRanks neutral
- NEWS Sanofi SA (SNY) Q4 2023 Earnings Report - Results, Call & Slides - tipranks.com — tipranks.com neutral
- NEWS Sanofi SA (SNY) Q2 2025 Earnings Report - Results, Call & Slides - TipRanks — TipRanks neutral
- NEWS Sanofi SA (SNY) Q1 2026 Earnings Report - Results, Call & Slides - TipRanks — TipRanks neutral
- NEWS Sanofi SA (SNY) Q1 2026 Earnings Report - Results, Call & Slides - tipranks.com — tipranks.com neutral
Generated 2026-08-09T07:47:22Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $43.00, but acceptable to hold if already in. Reasons: Thin upside margin: 8.2%; Weak growth. Chart setup: RSI 46 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Target $47.03 (+9.4%), stop $41.38 (−3.9%), A.R:R 1.6:1. Score 5.7/10, moderate confidence.
Take-profit target: $47.03 (+8.2% upside). Target $47.03 (+9.4%), stop $41.38 (−3.9%), A.R:R 1.6:1. Stop-loss: $41.38.
Thin upside margin: 8.2%; Weak growth; Below 200-day MA.
Sanofi trades at a P/E of 22.9 (forward 8.2). TrendMatrix value score: 6.5/10. Verdict: Hold.
30 analysts cover SNY with a consensus score of 3.8/5. Average price target: $54.
What does Sanofi do?Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides...
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.